You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Lixte terminates license agreement with Taipei Medical University
Cable Nets For Kids Enjoy Wide Carriage On Skinny Bundles
Power Forecast Briefing: Fleet Transformation, Under-Powered Markets, and Green Energy in 2018
Street Talk Episode 50 - Challenging The Legacy Core Bank Providers
Fed Poised To Relax Key Rules For Large Banks
Lixte Biotechnology Holdings Inc. terminated an exclusive license agreement with Taipei Medical University, effective Dec. 25.
The termination was due to the university's failure to file and seek approval from the U.S. FDA for an investigational new drug application to treat hepatocellular carcinoma using the company's licensed technology by Dec. 25.